Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Rennard, P. O‘Byrne, F. Radner, S. Peterson, E. Ekholm, B. Lindberg, D. Sin (Omaha, United States Of America; Hamilton, Vancouver, Canada; Lund, Sweden). Risks of diabetes mellitus and hyperglycaemic adverse events in patients with COPD taking inhaled corticosteroids. Eur Respir J 2011; 38: Suppl. 55, 3992

Member's Comments

No comment yet.

Related content which might interest you: Risks of diabetes mellitus and hyperglycaemic adverse events in patients with asthma taking inhaled corticosteroids Source: Annual Congress 2011 - Asthma management and response Year: 2011 Safety profile of COPD medications in COPD patients with concomitant diabetes mellitus Source: International Congress 2017 – COPD management Year: 2017 Long-term use of inhaled corticosteroids and the risk of type 2 diabetes in COPD Source: Virtual Congress 2020 – Comorbidities/multimorbidites and mortality in patients with chronic lung diseases Year: 2020 Metformin predispose acute exacerbations of COPD patients with insulin-dependent diabetes mellitus> Source: International Congress 2018 – COPD and extrapulmonary comorbidities Year: 2018 Adverse events in the treatment of patients with pulmonary tuberculosis combined with diabetes mellitus and without it. Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities Year: 2021 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016 Year: 2017 Impact of hyperglycaemia and comorbid diabetes mellitus on short and long-term outcome after COPD exacerbation Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement Year: 2013 Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities Source: Eur Respir Rev, 26 (145) 160123; 10.1183/16000617.0123-2016 Year: 2017 Impact of inhaled corticosteroids in patients with cardiovascular disease Source: Eur Respir Monogr 2020; 88: 251-263 Year: 2020 Risk of development of diabetes mellitus in patients with bronchial asthma Source: Eur Respir J 2006; 28: Suppl. 50, 323s Year: 2006 The evaluation of systemic inflammation in COPD patients comorbided with cardiovascular diseases or diabetes mellitus Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity Year: 2011 Comparison of COPD patients with and without diabetes mellitus Source: Virtual Congress 2020 – Diagnosis and management of COPD Year: 2020 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Development of diabetes mellitus in patients with bronchial asthma Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Glitazones are associated with reduced risk of COPD exacerbations and mortality among patients with diabetes Source: Annual Congress 2011 - COPD: burden of disease, imaging and management Year: 2011 Association between inhaled corticosteroid use in COPD and incidence or worsening of type2 diabetes Source: International Congress 2014 – Markers Year: 2014 Using cardioselective beta-blockers in patients with cardiovascular diseases and asthma Source: Eur Respir J 2007; 30: Suppl. 51, 69s Year: 2007 Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 The risk of hyperkalemia in COPD and asthma patients Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases Year: 2019 Long-term use of inhaled glucocorticoids in stable chronic obstructive pulmonary disease patients and risk of diabetes mellitus: systematic review of the literature Source: International Congress 2018 – Pharmacological management of COPD Year: 2018